Hanmi Science announced on the 30th that it delivered over 35,000 relief supplies to six disaster areas: Gapyeong in Gyeonggi Province, Sancheong in South Gyeongsang Province, Buk-gu in Gwangju, and Dangjin, Asan, and Yesan in South Chungcheong Province. The supplies included over 21,000 packs of the plant-based protein drink "Complete Soy Milk" and over 14,000 cans of the energy drink "Premium Recipe." The relief supplies will be delivered to disaster victims and volunteers helping with recovery efforts on the ground. A Hanmi Science representative said, "We hope the areas affected by the unexpected heavy rains recover quickly, allowing residents to return to their peaceful daily lives."
The Ministry of Food and Drug Safety announced on the 30th that it will accept pre-registration applications for the "2025 Global Bio Conference" (GBC) until August 29. The event will be held from September 3 for three days at the Pavilion Hotel in Seoul. Global regulatory authorities, the pharmaceutical industry, academia, patient organizations, and experts will gather to share the latest regulatory trends and developments in biopharmaceuticals and to discuss innovation and regulatory cooperation. Those wishing to participate can pre-register for free on the GBC website (www.gbckorea.kr).
KOLON Life Science's factory in Chungju announced on the 30th that it has received the "Women-Friendly Corporation" certification from Chungju City, North Chungcheong Province, and has held an official plaque presentation ceremony. The company was recognized for its efforts to build a sustainable organizational culture and improve the working environment for female employees. Recently, the company completed renovations to improve the environment of a female-only break room. CEO Kim Seon-jin stated, "The Women-Friendly Corporation certification is the result of a company culture that respects diversity and inclusion," adding, "We will create a workplace where everyone can grow together based on our philosophy of ESG (Environmental, Social, and Governance) management."
The specimen analysis organization GCCL announced on the 30th that it has signed a memorandum of understanding (MOU) with the Korea National Clinical Trial Center (KoNECT) for mutual cooperation in clinical research. Key points of the agreement include ▲ establishing a systematic basis for enhancing the quality capabilities of clinical trial specimen analysis and policy cooperation ▲ sharing the latest domestic and international medical and clinical information ▲ exchanging technical and academic information ▲ and cooperating on domestic and international promotion. GCCL CEO Cho Kwan-gu noted, "We will provide differentiated clinical specimen analysis services to the global market in collaboration with public institutions."
Medytox announced on the 30th that it is holding an event on its official Naver blog to celebrate the new TV advertisement for its premium hyaluronic acid (HA) filler "NEURAMIS." Participants can add Medytox's official blog as a neighbor and leave their impressions after watching the new advertisement. A draw will give 100 people ▲ a photo card with an autograph from actor Park Hyung-sik and a set of "Newraderm Calming Mist" (20 people) ▲ and mobile coffee gift coupons (80 people). Winners will be announced on the 20th.
Ildong Pharmaceutical announced on the 30th that it will acquire 1,798,347 shares of its health supplement subsidiary, Ildong Bioscience, for approximately 14.2 billion won. Ildong Pharmaceutical's equity interest in Ildong Bioscience will be 22.5%. Ildong Pharmaceutical explained that the share acquisition is intended to establish a value chain for health supplements. The share acquisition is scheduled for the 31st.
Qurient announced on the 30th that it has submitted a clinical trial application and clinical trial drug materials for its candidate treatment for chronic graft-versus-host disease, "Adricitinib," to the European Medicines Agency (EMA). Chronic graft-versus-host disease is a chronic inflammatory and fibrotic condition that occurs in 30% to 70% of hematopoietic stem cell transplant patients. The company plans to expand its drug development in Europe in addition to the ongoing clinical trials in the United States.
The Catholic University of Korea's Seoul St. Mary's Hospital announced on the 30th that a research team led by Professors Hong Sung-hoo and Bang Seok-hwan from the Department of Urology has published research findings demonstrating the clinical superiority of "single-port robotic retroperitoneal partial nephrectomy." This surgery removes kidney tumors through small incisions without opening the abdominal cavity. The research team reduced the surgery time compared to previous methods. Patients recovered quickly. This research received an award in the international submission paper category at the 31st Korean Urological Association's regular academic conference.